Seelos Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Raj Mehra
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Park Avenue New York City NY United States of America 10022
- IPO Date
- Apr 19, 1999
- CIK
- 0001017491
- Website
- seelostherapeutics.com
- Similar Companies
- Business
- Seelos Therapeutics, Inc. was formerly a clinical-stage biopharmaceutical entity dedicated to advancing novel therapies for central nervous system disorders and various rare diseases, based in New York, New York. The company recently underwent significant restructuring, having filed for Chapter 11 bankruptcy in November 2024 and subsequently had its key therapeutic programs acquired by GLD Partners, LP in October 2025. Previously, its common stock was delisted from Nasdaq in October 2024 and transitioned to the over-the-counter market. Among the core assets now being advanced by GLD Partners is SLS-002, an intranasal racemic ketamine formulation. This program aims to address acute suicidal ideation and behavior in individuals with major depressive disorder, with FDA guidance supporting its progression into a Phase 3 trial. SLS-002 is also being evaluated through a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity for its potential in treating post-traumatic stress disorder. Another significant program acquired is SLS-005, an intravenous formulation of trehalose, which was under investigation for amyotrophic lateral sclerosis and other neurodegenerative conditions like Sanfilippo syndrome and spinocerebellar ataxia. While earlier studies for SLS-005 in ALS did not meet their primary endpoints, GLD plans to progress this asset into adaptive Phase 2/3 studies. The original pipeline also included preclinical initiatives such as SLS-004 and SLS-007, both gene therapy candidates for Parkinson's disease, and other early-stage programs for various neurological and inflammatory indications.
Seelos Announces Second Postponement of its Annual Meeting of Stockholders
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
Seelos Announces Postponement of its Annual Meeting of Stockholders
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
Seelos Therapeutics Announces Closing of Public Offering
Why Are Stocks Up Today?
Why Is Seelos Therapeutics (SEEL) Stock Down 42% Today?
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
Seelos Therapeutics Announces Proposed Public Offering